Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation

Bögeholz, Jan; Russkamp, Norman F.; Wilk, C. Matthias; Gourri, Elise; Haralambieva, Eugenia; Schanz, Urs; Mueller, Nicolas J.; Manz, Markus G.; Müller, Antonia

doi:10.1016/j.bbmt.2019.10.027

Cited by 7 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that the immaturity of donor-derived lymphocytes, the decrease in recipient plasma cells, and the low levels of antibodies resulting from transplantation lead to a loss of immunity to pathogens for which immunity had been acquired during childhood, either through vaccination or infection [ 7 ]. This loss of protection following HSCT has been described for multiple pathogens, such as Streptococcus pneumoniae [ 8 , 9 , 10 , 11 ], rubella and mumps [ 11 ], hepatitis B [ 12 ], tetanus [ 8 ], diphtheria, Haemophilus influenzae or polio [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

Rodríguez-Mora

Pérez-Lamas

Sainero

et al. 2023

Cancers

View full text Add to dashboard Cite

The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (n = 11) or autologous (n = 18) HSCT. All participants had low but protective levels of neutralizing IgGs against SARS-CoV-2 after HSCT despite B-cell lymphopenia and immaturity. Although antibody-dependent cellular cytotoxicity was impaired, direct cellular cytotoxicity was similar to healthy donors in participants with autologous-HSCT, in contrast to individuals with allogeneic–HSCT, which severely deteriorated. No significant changes were observed in the immune response before and after HSCT. During follow-up, all reported post-HSCT SARS-CoV-2 infections were mild. This data emphasizes that COVID-19 vaccination is effective, necessary, and safe for individuals with OHD and also supports the persistence of some degree of immune protection after HSCT, at least in the short term, when patients cannot yet be revaccinated.

show abstract

Section: Introductionmentioning

confidence: 99%

Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

Rodríguez-Mora

Pérez-Lamas

Sainero

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…A study of live-attenuated varicella zoster vaccine noted that donor vaccination is safe, but whether it confers significant protection for patients requires further study. 9 Bogeholz et al 10 indicated in a study of measles, mumps, and rubella antibody titers in allo-HSCT recipients that donor immune status did not appear to have an influence on antibody protection after HSCT. During our observation period, no patients were found with SARS-CoV-2 infection after transplantation, this probably be related to the absence of the COVID-19 epidemic in the area of our center.…”

mentioning

confidence: 99%

The safety and short‐term outcomes of allogeneic hematopoietic stem cell transplantation with donor vaccination for COVID‐19

Ding

Shen

Fan

et al. 2022

MedComm

View full text Add to dashboard Cite

Dear Editor,Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread rapidly across the globe, threatening the health and safety of an increasing number of people. It has been shown that the SARS-CoV-2 vaccine is effective in reducing the chance of COVID-19 infection and the severity of the disease. [1][2][3] To control the COVID-19 pandemic, an increasing number of studies are calling for people to receive the SARS-CoV-2 vaccine, 4,5 and the Chinese government is also advocating universal vaccination. Patients with malignant hematologic diseases are mostly immunodeficient, 6 and recipients are immunosuppressed when undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). 7 One report on donorderived vaccination indicated that vaccination could induce antigen-specific immune responses in patients after allo-HSCT. 8 In addition, most COVID-19 vaccines in China, different from prevailing types in other countries, are inactivated SARS-CoV-2 vaccines. Hitherto, there are no reports on whether the vaccine will induce immune responses impacting immune reconstitution, complications, and outcomes of recipients. Therefore, many clinicians and patients in China hesitate to choose a COVID-19-vaccinated person as a donor, which partially inspires us to collect cases of donors who received SARS-CoV-2 vaccination to explore the impact of donor vaccination with SARS-CoV-2 vaccine on recovery and outcomes after transplantation in recipients.From March 2021 to December 2021, we retrospectively collected data on a total of 253 patients who received allo-HSCT at the First Affiliated Hospital of Soochow University, none of them had ever had COVID-19 prior to transplantation, and none of them were vaccinated for COVID-19 before transplantation and during the posttransplant follow-up period. All donors and patients provided written informed consent for the protocol approved by The This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients

Kawamura

Wada

Nakasone

et al. 2021

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation

Cited by 7 publications

References 42 publications

Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

The safety and short‐term outcomes of allogeneic hematopoietic stem cell transplantation with donor vaccination for COVID‐19

Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients

Contact Info

Product

Resources

About